Clevudine

Clevudine
Systematic (IUPAC) name

1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5- (hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine- 2,4-dione
Clinical data
Routes of administration	Oral
Identifiers
CAS Number	69256-17-3^Y
ATC code	J05AF12 ^[1]
PubChem	CID 73115
ChemSpider	65894^N
UNII	IN51MVP5F1^N
KEGG	D03537^Y
ChEMBL	CHEMBL458875^N
Chemical data
Formula	C₁₀H₁₃FN₂O₅
Molar mass	260.219 g/mol
SMILES O=C/1NC(=O)N(\C=C\1C)[C@H]2O[C@H]([C@H](O)[C@H]2F)CO
InChI InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m0/s1^N Key:GBBJCSTXCAQSSJ-XQXXSGGOSA-N^N
^NY (what is this?) (verify)

Clevudine (INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir.

Under license from Bukwang, Pharmasset was developing the drug, but its phase III clinical trial (international, multicenter, randomized, double-blind, 96 week QUASH studies) was terminated due to some myopathy cases in patients. Its approval in South Korea was revoked following these findings. Researchers in South Korea are testing clevudine at lower doses in combination with adefovir for continued use. ^[2]

It is a nucleoside analog.^[3]

References

↑ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Archived from the original on 2008-05-06. Retrieved 2008-09-05.
↑ Tak WY, Yang JM, Kim BI, Baik SK, Cheon GJ, Byun KS, Kim DY, Yoo BC; et al. (May 2014). "A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients.". Hepatology International 8 (3): 375–381. doi:10.1007/s12072-014-9537-5. PMID 25101150.
↑ Lee HS, Chung YH, Lee K; et al. (May 2006). "A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B". Hepatology 43 (5): 982–8. doi:10.1002/hep.21166. PMID 16628625.

DNA virus antivirals (primarily J05, also S01AD and D06BB)

Baltimore I

Herpesvirus

DNA-synthesis
inhibitor

TK activated

Purine analogue	guanine (Aciclovir^#/Valaciclovir Ganciclovir/Valganciclovir Penciclovir/Famciclovir) adenine (Vidarabine)

Pyrimidine analogue	uridine (Idoxuridine Trifluridine (+tipiracil) Edoxudine) thymine (Brivudine) cytosine (Cytarabine)

Not TK activated

Foscarnet

Other

HPV/MC

Vaccinia

assembly: Rifampicin

Poxviridae

Methisazone

Hepatitis B (VII)

Multiple/general

Nucleic acid inhibitors	Cidofovir

Interferon	Interferon alfa 2b Peginterferon alfa-2a

Multiple/unknown	Ribavirin^#/Taribavirin^† Moroxydine

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Friday, December 18, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.